Dosing the first patient in MODeFIRe-1 is an important step in advancing MRT-2359 as a potential therapy for patients with mCRPC with AR mutations, a population with limited therapeutic options,” said ...

PROTEUS results reshape high‑risk localized prostate cancer care, adding apalutamide plus androgen deprivation before surgery as a new option. The phase 3 PROTEUS trial data may add a new ...

A 1-year period of intensified androgen receptor blockade prolonged prostate-specific antigen progression-free survival (PSA-PFS) compared with androgen deprivation therapy (ADT) alone for patients ...

At a median follow-up of 21.5 months, ADT plus apalutamide significantly prolonged median PSA progression-free survival compared with ADT monotherapy (24.9 vs 20.3 months; hazard ratio [HR], 0.52).

SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...

Johnson & Johnson (JNJ) reported late-stage clinical trial results showing that adding its prostate cancer drug apalutamide to hormone therapy before and after surgery improved outcomes for men with ...

Androgen deprivation therapy plus apalutamide was significantly favored over ADT plus placebo for event-free survival. HealthDay News — Perioperative treatment with apalutamide and androgen ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Post hoc analysis of rPFS and OS from the TALAPRO-2 (TP-2) study: Genomic subgroups based on likelihood of BRCA or HRR gene alteration status. This is an ASCO Meeting Abstract from the 2024 ASCO ...

BOSTON, May 31, 2026 – High-risk localized and locally advanced prostate cancer patients treated with apalutamide — a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus ...

Recently published Non-Metastatic Prostate Cancer Market Insights report includes a comprehensive understanding of current ...